JP Morgan Chase’s Acadia Pharmaceuticals ACAD Stock Holding History

JP Morgan Chase’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-27,000	Closed	-$415K	–	7363
2024 Q3	$415K	Hold	27,000	–	–	﹤0.01%	5023
2024 Q2	$439K	Sell	27,000 -73,000	-73%	-$1.18M	﹤0.01%	4761
2024 Q1	$1.85M	Buy	+100,000	New	+$2.48M	﹤0.01%	3905
2020 Q1	–	Sell	-29,400	Closed	-$1.26M	–	5241
2019 Q4	$1.26M	Buy	+29,400	New	+$1.28M	﹤0.01%	3689
2019 Q1	–	Sell	-20,000	Closed	-$323K	–	5723
2018 Q4	$323K	Sell	20,000 -65,000	-76%	-$1.26M	﹤0.01%	4356
2018 Q3	$1.76M	Buy	+85,000	New	+$1.34M	﹤0.01%	3543
2016 Q2	–	Sell	-215,700	Closed	-$6.03M	–	4744
2016 Q1	$6.03M	Buy	+215,700	New	+$4.7M	﹤0.01%	2098

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase's ACAD Position: Q1 2026 in Review

JP Morgan Chase reduced its Acadia Pharmaceuticals (ACAD) stake by 2.9% in Q1 2026, selling an estimated $185K and leaving 263,091 shares worth $5.54M. The position accounts for ﹤0.01% of the portfolio, ranked #3233.

JP Morgan Chase first reported a position in ACAD in Q2 2013 and has held it in 52 quarters since. The position peaked at $72.1M in Q3 2017. 341 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

JP Morgan Chase held 263,091 shares of Acadia Pharmaceuticals worth $5.54M as of Q1 2026.
JP Morgan Chase sold 7,735 Acadia Pharmaceuticals shares in Q1 2026, an estimated $185K.
Acadia Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3233 holding.
JP Morgan Chase first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
JP Morgan Chase's Acadia Pharmaceuticals position peaked at $72.1M in Q3 2017.
341 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.